Zhengbin Yao
CIK: 0001326228
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 30, 2026ALMS
ALUMIS INC.
Award(A)Direct3.6K shares- - Feb 2, 2026AVBP
ArriVent BioPharma, Inc.
Award(A)DirectStock Option (right to buy)
550K shares- - Jul 30, 2025ALMS
ALUMIS INC.
Award(A)DirectStock Option (Right to Buy)
49.8K shares- - Feb 3, 2025AVBP
ArriVent BioPharma, Inc.
Award(A)DirectStock Option (right to buy)
380K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 30, 2026 |  ALMS ALUMIS INC. | Award(A) | 3,553 | - | $0 | Direct |
| Feb 2, 2026 |  AVBP ArriVent BioPharma, Inc. | Award(A) Stock Option (right to buy) | 550,000 | - | - | Direct |
| Jul 30, 2025 | ALMS ALUMIS INC. | Award(A) Stock Option (Right to Buy) | 49,800 | - | - | Direct |
| Feb 3, 2025 | AVBP ArriVent BioPharma, Inc. | Award(A) Stock Option (right to buy) | 380,000 | - | - | Direct |
1-4 of 4 transactions
About Yao Zhengbin
Yao Zhengbin (SEC CIK 0001326228) files insider reports with the SEC as Director of ALUMIS INC. (ALMS) and President and CEO of ArriVent BioPharma, Inc. (AVBP).
Signal8 holds 4 ownership filings by Yao Zhengbin, all Form 4s, filed between Feb 14, 2025 and Jul 2, 2026. Those filings report 4 transactions, from Feb 3, 2025 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Yao Zhengbin's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Yao Zhengbin
Other insiders filing for ALUMIS INC. (ALMS)
- AKKARAJU SRINIVAS, Director
- Schroer John R., Chief Financial Officer
- Pangali Sanam, Chief Legal Officer
- Hardiman Roy C., Chief Business & Strategy Ofcr
- Goldstein David M, Chief Scientific Officer
- Drappa Jorn, Chief Medical Officer